Condor Capital Management Has $5.15 Million Position in Novo Nordisk A/S (NYSE:NVO)

Condor Capital Management grew its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 166.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 59,846 shares of the company's stock after buying an additional 37,365 shares during the quarter. Condor Capital Management's holdings in Novo Nordisk A/S were worth $5,148,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Folketrygdfondet lifted its position in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Folketrygdfondet now owns 8,903,938 shares of the company's stock worth $765,917,000 after purchasing an additional 40,313 shares in the last quarter. Sustainable Growth Advisers LP lifted its position in shares of Novo Nordisk A/S by 23.6% in the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock worth $459,416,000 after purchasing an additional 1,021,498 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Novo Nordisk A/S in the fourth quarter worth $404,910,000. WCM Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 1.0% in the fourth quarter. WCM Investment Management LLC now owns 4,031,124 shares of the company's stock worth $345,588,000 after purchasing an additional 40,475 shares in the last quarter. Finally, Amundi lifted its position in shares of Novo Nordisk A/S by 26.4% in the fourth quarter. Amundi now owns 3,311,456 shares of the company's stock worth $283,615,000 after purchasing an additional 692,567 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several analysts have issued reports on the stock. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Friday. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Moderate Buy" and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock traded down $1.91 on Friday, hitting $76.88. The stock had a trading volume of 5,876,147 shares, compared to its average volume of 5,421,183. Novo Nordisk A/S has a twelve month low of $73.80 and a twelve month high of $148.15. The business's 50 day moving average is $83.34 and its two-hundred day moving average is $100.74. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The stock has a market cap of $344.98 billion, a price-to-earnings ratio of 23.37, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio is currently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.